Dr. Reddy's Laboratories Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Erez Israeli
- Full Time Employees
- 27,527
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 8-2-337, Road No. 3 Hyderabad TS India 500034
- IPO Date
- Jan 1, 1986
- Website
- drreddys.com
- Similar Companies
- Business
- Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company that develops, manufactures and markets generics, active pharmaceutical ingredients, biosimilars, branded generics and over-the-counter products worldwide; it offers finished dosage formulations including tablets, capsules, injectables and topical creams across therapeutic areas such as gastroenterology, cardiovascular, oncology, pain management, anti-infectives, diabetology, dermatology and pediatrics. Founded in 1984 by Kallam Anji Reddy and headquartered in Hyderabad, India, with U.S. headquarters in East Brunswick, New Jersey, the company operates manufacturing facilities in India, the UK and other regions, serving markets in North America, Europe, India, Russia and emerging economies. Its portfolio includes key active pharmaceutical ingredients like Abiraterone Acetate, Canagliflozin, Ciprofloxacin Hydrochloride, Ramipril and Ibuprofen; over 190 medications; diagnostic kits; and biotechnology products, supported by pharmaceutical services for custom development and contract manufacturing. Recent developments include a June 2025 collaboration with Alvotech to co-develop, manufacture and commercialize a pembrolizumab (Keytruda) biosimilar for global markets; acquisition of Haleon's global Nicotinell nicotine replacement therapy business (excluding the U.S.) for over Rs 5,000 crore; acquisition of U.S.-based MenoLabs to enter women's nutritional wellness; purchase of Novartis's Cidmus cardiovascular brand in India for Rs 456 crore; INR 700 crore investment in biosimilars and API capacity expansion, elevating annual capex to INR 1,400 crore; plans to launch generic weight-loss drugs in 87 countries including Canada, India and Brazil; and introduction of products like Toripalimab for nasopharyngeal carcinoma, a bevacizumab biosimilar in the UK, and Lenacapavir for HIV in partnership with Gilead Sciences.
Company News
Dr. Reddy’s Laboratories (NYSE:RDY) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Arrowstreet Capital Limited Partnership Buys Shares of 102,643 Dr. Reddy’s Laboratories Ltd $RDY